ClinicalTrials.gg
CompletedNCT07181694Updated Jul 28, 2026

A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

A Phase 1 interventional study of Adalimumab (BCD-057) 100 mg/mL and Adalimumab (BCD-057) 50 mg/mL in Healthy Adult Male, sponsored by Biocad. Completed at 4 sites in Russia. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Biocad · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2025, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The aim of this study is to establish comparability of pharmacokinetic parameters and similarity of the safety and immunogenicity profiles of single subcutaneous doses of BCD 057 100 mg/mL and BCD-057 50 mg/mL, as well as BCD-057 100 mg/mL and Humira 100 mg/mL, in healthy subjects. The study is conducted in a population of healthy male subjects aged 18-45 years inclusive at the time of signing the ICF, with a body mass index in the range of 18.5 to 30.0 kg/m2.

Read the detailed description

The study includes following periods:

  • Screening (not more than 14 days)
  • Main period (Day 1 to Day 71)

Subjects meeting the eligibility criteria will be randomized with equal probability into one of three groups:

  • ADA100 group - subjects will receive a single subcutaneous injection of BCD-057 at a dose of 40 mg/0.4 mL
  • ADA50 group - subjects will receive a single subcutaneous injection of BCD-057 at a dose of 40 mg/0.8 mL
  • HUM100 group - subjects will receive a single subcutaneous injection of Humira at a dose of 40 mg/0.4 mL

During randomization, subjects will be stratified by the following criterion:

  • Body weight (\<75 kg or ≥75 kg)
02

Conditions studied

  • Healthy Adult Male

Keywords

  • Tumor Necrosis Factor Inhibitors
  • Anti-Inflammatory Agents
  • Adalimumab
  • Monoclonal Antibody
  • Pharmacokinetics
03

In context

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signing the Form of the study.
  2. Men aged 18-45 years inclusive at the time of signing the Informed Consent Form.
  3. (BMI) in the range of 18.5-30.0 kg/m2.
  4. The confirmed "healthy" status based on the conventional clinical and laboratory assessments and investigations obtained as screening.
  5. Hemodynamic parameters within the normal range: systolic blood pressure (SBP) in the range of 100-130 mmHg, diastolic (DBP) in the range of 60-90 mmHg, wrist pulse rate 60-90 bpm, obtained at screening.
  6. data normal for the age (no ischemia, arrhythmia, conduction disorders).
  7. No chronic infections (, or C) and no history of chronic inflammatory diseases.
  8. No signs of active or latent tuberculosis according to screening X-ray and tuberculosis test results.
  9. No acute infections within 4 weeks prior to the date of randomization.
  10. The ability of the subject to follow the Protocol procedures, according to the Investigator.
  11. No history of alcoholism or drug addiction and negative test results for alcohol, psychotropic and narcotic substances, psychoactive drugs at screening and before the IP administration.
  12. Willingness of subjects to use condoms during any sexual contact by penetration with persons of any sex, including pregnant women, starting from the signing of the Informed Consent Form, during the study and for 5 months after the IP administration. This requirement does not apply to subjects who have undergone surgical sterilization (bilateral orchiectomy).
  13. Willingness to refuse to donate sperm and conceive a child starting from the signing of the Informed Consent Form, during the study and for 5 months after the IP administration.
  14. Willingness not to drink alcohol within 24 hours before and after the IP administration, within 24 hours before each scheduled visit.
  15. Willingness to refrain from smoking within 2 hours before the IP administration and then 2 hours before each measurement of blood pressure (BP), wrist pulse rate, respiratory rate, blood sampling, ECG.
  16. Willingness to refrain from vaccination with (e.g., intranasal influenza, measles, mumps, rubella, polio, BCG, yellow fever, chickenpox, and typhoid TY21a vaccines) throughout the study.
  17. Willingness to refrain from taking any medications, including over-the-counter drugs, vitamins and food supplements, with the exception of drugs prescribed by the Investigator for the treatment of AEs, throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Mental illness or other conditions that may, in the Investigator's opinion, affect the subject's ability to comply with the Study Protocol.
  2. Any significant, in the Investigator's opinion, surgical procedures performed less than 30 days before the screening examination and potentially affecting clinical study results.
  3. A history of allergic reactions (anaphylactic shock or multiple drug allergy according to the Investigator's assessment).
  4. Known allergy or intolerance to monoclonal antibody products (murine, chimeric, humanized, fully human) or any other components of the IP.
  5. Impossibility of installing a venous catheter for collecting blood samples (e.g., due to skin disorders at the venipuncture sites).
  6. Administration and use of the following drugs:

    1. Past use of adalimumab or any other drugs that inhibit tumor necrosis factor alpha.
    2. Regular oral or parenteral administration of any medicinal products, including over-the-counter drugs, vitamins, and dietary supplements, less than 14 days prior to the estimated date of randomization.
    3. Taking medications, including over-the-counter drugs, which have a pronounced effect on hemodynamics and liver function (barbiturates, omeprazole, cimetidine, etc.), less than 30 days before the estimated date of randomization.
    4. Using drugs that affect the immune status (cytokines and their inducers, , etc.) less than 30 days before the estimated date of randomization.
    5. Systemic use of antibacterial, antifungal, antiviral or antiprotozoal drugs less than 30 days before the estimated date of randomization.
    6. Vaccination with within 4 weeks before the estimated date of randomization.
  7. Positive results of screening tests for , and C viruses.
  8. Results of conventional laboratory tests or investigations out of the reference ranges accepted at the study sites.
  9. Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, kidneys, blood.
  10. Acute infectious diseases less than 4 weeks before the estimated date of randomization, as well as chronic and other diseases that, in the Investigator's opinion, may affect the pharmacokinetics, safety, and immunogenicity of the IP.
  11. Smoking more than 10 cigarettes a day.
  12. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 50 mL of spirits) or a history of alcoholism, drug addiction, or drug abuse.of blood or plasma within 60 calendar days prior to the expected date of randomization.
  13. Donation of ≥450 mL of blood or plasma within 60 calendar days prior to the expected date of randomization.
  14. Participation in any clinical studies in less than 90 calendar days before the date of randomization, if the subject received a medicinal product during the clinical study.
  15. Previous participation in the same study if the subject was randomized and received the IP during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
444 participants (actual)

Study arms

  • Experimental
    ADA100

    Subjects will receive a single subcutaneous injection of BCD-057 at a dose of 40 mg/0.4 mL

    Drug: Adalimumab (BCD-057) 100 mg/mL

  • Active comparator
    ADA50

    Subjects will receive a single subcutaneous injection of BCD-057 at a dose of 40 mg/0.8 mL

    Drug: Adalimumab (BCD-057) 50 mg/mL

  • Active comparator
    HUM100

    Subjects will receive a single subcutaneous injection of Humira at a dose of 40 mg/0.4 mL

    Drug: Adalimumab (Humira) 100 mg/mL

Interventions

  • DrugAdalimumab (BCD-057) 100 mg/mL

    Drug page: Adalimumab

    Single subcutaneous injection

  • DrugAdalimumab (BCD-057) 50 mg/mL

    Drug page: Adalimumab

    Single subcutaneous injection

  • DrugAdalimumab (Humira) 100 mg/mL

    Drug page: Adalimumab

    Single subcutaneous injection

06

What researchers measure

Primary outcomes

  1. AUC(0-∞)

    Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

  2. Cmax

    Maximum Concentration

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

Secondary outcomes

  1. AUC(0-1680)

    Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

  2. Tmax

    Time to Reach Maximum Concentration

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

  3. T½

    Half-life Period

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

  4. Vd

    Volume of Distribution

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

  5. Kel

    Elimination Rate Constant

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

  6. Cl

    Clearance

    Time frame: Before drug administration and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours after drug administration

07

Study locations

4 sites
  • I.M. Sechenov First Moscow State Medical University
    Moscow, 119435, Russia
  • LLC "X7 Clinical Research"
    Saint Petersburg, 194156, Russia
  • LLC "Research Center Eco-Safety"
    Saint Petersburg, 196143, Russia
  • LLC "X7 Clinical Research"
    Saint Petersburg, 199178, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Feb 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 18, 2025
StartActual
Mar 12, 2025
Primary completionActual
Feb 12, 2026
CompletionActual
Feb 12, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07181694
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Mar 12, 2025
Primary completion
Feb 12, 2026
Completion
Feb 12, 2026
Last update
Jul 28, 2026

Study contacts

Arina V Zinkina-Orikhan
study director · Biocad

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion